AbbVie Points 3rd Circ. To School Board Ruling In FTC Case

Law360 (August 31, 2020, 9:42 PM EDT) -- AbbVie Inc. has told the Third Circuit that a recent ruling involving alleged abuse of the litigation process supports the company's bid to evade Federal Trade Commission claims that it delayed generic competition for its AndroGel testosterone treatment through sham lawsuits.

AbbVie filed a letter with the Third Circuit on Friday directing it to a decision from earlier last week in a dispute between an anti-union activist and the Pennsylvania School Boards Association. The activist alleged his civil rights were violated when the association sued him in state court over his filing of hundreds of information requests under Pennsylvania's Right-To-Know Law.

Notably, AbbVie said in its...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!